Amdocs Limited (NASDAQ:DOX – Get Free Report)’s share price reached a new 52-week low during trading on Tuesday . The company traded as low as $49.90 and last traded at $51.69, with a volume of 2666214 shares changing hands. The stock had previously closed at $51.47.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on DOX. Weiss Ratings reissued a “hold (c-)” rating on shares of Amdocs in a report on Friday, May 8th. Stifel Nicolaus reduced their price target on shares of Amdocs from $88.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Cfra downgraded shares of Amdocs to a “sell” rating in a report on Thursday, May 14th. Finally, Wall Street Zen lowered shares of Amdocs from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $86.67.
Read Our Latest Research Report on Amdocs
Amdocs Stock Performance
Amdocs (NASDAQ:DOX – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The technology company reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.01. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Amdocs had a return on equity of 19.77% and a net margin of 11.81%.The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.78 EPS. Equities research analysts forecast that Amdocs Limited will post 6.56 EPS for the current year.
Amdocs Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.569 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date is Tuesday, June 30th. Amdocs’s dividend payout ratio is presently 45.60%.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of DOX. WealthCollab LLC increased its stake in Amdocs by 94.5% in the 3rd quarter. WealthCollab LLC now owns 356 shares of the technology company’s stock worth $29,000 after buying an additional 173 shares in the last quarter. BOK Financial Private Wealth Inc. purchased a new position in shares of Amdocs in the fourth quarter valued at about $37,000. Los Angeles Capital Management LLC bought a new position in shares of Amdocs in the fourth quarter worth about $39,000. Advisory Services Network LLC bought a new position in shares of Amdocs in the third quarter worth about $42,000. Finally, CIBC Private Wealth Group LLC grew its position in shares of Amdocs by 190.2% during the third quarter. CIBC Private Wealth Group LLC now owns 595 shares of the technology company’s stock worth $49,000 after purchasing an additional 390 shares in the last quarter. Hedge funds and other institutional investors own 92.02% of the company’s stock.
About Amdocs
Amdocs (NASDAQ: DOX) is a global software and services provider specializing in solutions for communications, media and entertainment companies. The company designs, develops and integrates revenue management, customer experience and digital services platforms that enable service providers to launch and monetize new offerings, streamline operations and enhance subscriber engagement. Amdocs’ product suite encompasses billing and order management, customer relationship management, digital commerce and network function virtualization, supported by professional services for implementation, integration and managed operations.
Founded in 1982 and structured as a separate public company in 1998, Amdocs has its corporate headquarters in Chesterfield, Missouri, and maintains major development centers in Ra’anana, Israel.
Featured Articles
- Five stocks we like better than Amdocs
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.
